Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326228 | 1.00 | LMNA (0.46) | LMNAL3MBTL1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL7498186 | 0.77 | CHRNB2 (0.55) | LMNAL3MBTL1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6328393 | 0.71 | GAA (0.52) | LMNAL3MBTL1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6325147 | 0.71 | CHRNB2 (0.69) | LMNAL3MBTL1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6328394 | 0.71 | GAA (0.52) | LMNAL3MBTL1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL6325141 | 0.71 | CHRNB2 (0.69) | LMNAL3MBTL1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL17037354 | 0.69 | KMT2A (0.56) | LMNAL3MBTL1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL9839137 | 0.67 | CHRNB2 (0.57) | LMNAL3MBTL1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL9839133 | 0.67 | CHRNB2 (0.57) | LMNAL3MBTL1CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL8783711 | 0.67 | NPC1 (0.50) | LMNAL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078259-A1 | Di-substituted imineheterocyclic compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-04-24 | — | — | US | claimed |
| US-6900202-B2 | Di-substituted imineheterocyclic compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-05-31 | — | — | US | disclosed |
| US-20030078259-A1 | Di-substituted imineheterocyclic compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078259-A1 | Di-substituted imineheterocyclic compounds | CHRNA2, CHRNA7, CHRNB2 | LMNA 3406/4885L3MBTL1 4236/4885CHRNB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.